Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: VYNE

VYNE Therapeutics Inc.

Healthcare | Biotechnology
$28.56
Market Cap$950M
Volume93.3K
EPS (FY2025)$-0.62

VYNE Therapeutics Inc. (NASDAQ: VYNE) is a $950M biotechnology company trading at $28.56. Figures from SEC EDGAR and market feeds; updated 2026-10-11 02:16 UTC.

What VYNE Therapeutics Inc. does

VYNE is a clinical-stage biopharmaceutical company developing therapies for inflammatory and immune-mediated conditions. The company holds exclusive worldwide rights to small molecule BET inhibitor compounds licensed from Tay Therapeutics, including both pan-BD inhibitors and BD2-selective inhibitors. VYNE's former lead program, repibresib gel, was being tested for nonsegmental vitiligo but did not meet its primary endpoint and was discontinued. The company is currently developing VYN202, an oral BD2-selective BET inhibitor designed to target pro-inflammatory gene expression.

Summarized from VYNE Therapeutics Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

VYNE no longer appears among SEC's registered filers -- it may have been acquired, merged, or delisted. The figures on this page reflect the company's final filings and are no longer refreshed.
Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.

Key facts

Quote
Price$28.56
Market cap$950M
Volume93.3K shares
Valuation
EPS (FY2025)$-0.62
Price/book34.22×

Revenue, margins & earnings

FY2021: net loss $73M on revenue $931,000$931,000FY2021FY2022: net loss $23M on revenue $477,000$477,000FY2022FY2023: net loss $28M on revenue $424,000$424,000FY2023FY2024: net loss $40M on revenue $501,000$501,000FY2024FY2025: net loss $26M on revenue $570,000$570,000FY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-07-30
  • 2026-07-3010% OwnerOther-133,290—
  • 2026-07-3010% OwnerOther133,290—
  • 2026-07-29DirectorAward185,798—
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does VYNE Therapeutics Inc. do?

VYNE is a clinical-stage biopharmaceutical company developing therapies for inflammatory and immune-mediated conditions.

What is VYNE's valuation?

VYNE trades at $28.56, as of 2026-10-11.

When did VYNE last file with the SEC?

VYNE Therapeutics Inc.'s most recent SEC filing on record is a 8-K filed 2026-07-30. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings and public market data feeds, fetched 2026-10-11 02:16 UTC. This page is also available as JSON at /api/data?ticker=VYNE and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for VYNE and 5,000+ tickers.

Create a free account — keep VYNE
For your agent
GET /api/data?ticker=VYNE

This page as JSON via rel="alternate" · REST API docs · MCP server (62 tools) · llms.txt